BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 18, 2010
View Archived Issues
Still Seeking Partner, Anadys Adds $25M for HCV Drug Trial
Having yet to sign a partnership for hepatitis C drug ANA598, Anadys Pharmaceuticals Inc. is pulling in $25 million in a public offering to support an upcoming Phase IIb study of the non-nucleoside polymerase inhibitor. (BioWorld Today)
Read More
NewCo News: FerroKin to Eliminate Iron Overload with 1 Dose/Day
Read More
Worms, Women's Fertility Decline In Similar Ways
Read More
Questcor Gains FDA OK for Infantile Spasms Drug
Read More
Stock Movers
Read More
Corrections & Clarifications
Read More
Other News To Note
Read More
Earnings Roundup
Read More
Clinic Roundup
Read More
Bench Press
Read More